Medicare Enrolled

Dr. Kavitha Pinnamaneni, M.D.

Hematology & Oncology · Lufkin, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
1202 W FRANK AVE, Lufkin, TX 75904
9366376415
In practice since 2006 (19 years)
NPI: 1669493573 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Pinnamaneni from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Pinnamaneni? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Pinnamaneni

Dr. Kavitha Pinnamaneni is a hematology & oncology in Lufkin, TX, with 19 years in practice. Based on federal Medicare data, Dr. Pinnamaneni performed 20,885 Medicare services across 1,419 unique beneficiaries.

Between the years covered by Open Payments, Dr. Pinnamaneni received a total of $2,834 from 32 pharmaceutical and/or device companies across 93 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Pinnamaneni is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 32% volume in TX$ $2,834 industry payments

Medicare Practice Summary

Medicare Utilization ↗
20,885
Medicare services
Top 32% in TX for hematology & oncology
1,419
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,099 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Epoetin alfa injection (Retacrit) for anemia5,042$6$45
Contrast dye for imaging (iodine-based)4,304$0$1
Dexamethasone injection (steroid)2,758$0$5
Anti-nausea injection (Aloxi/palonosetron)1,480$1$55
Injection, granisetron hydrochloride, 100 mcg1,310$0$15
Blood draw (venipuncture)1,140$8$25
Complete blood count (CBC) with differential1,122$8$65
High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml601$0$1
Office visit, established patient (30-39 min)510$94$350
Injection of additional new drug or substance into vein458$12$80
Administration of chemotherapy into vein, 1 hour or less418$98$550
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less309$21$205
Injection, zoledronic acid, 1 mg228$6$274
Drug injection, under skin or into muscle216$11$65
Office visit, established patient (20-29 min)129$67$250
Administration of additional new drug or substance into vein, 1 hour or less128$50$275
Administration of chemotherapy into vein, each additional hour112$22$225
Injection, diphenhydramine hcl, up to 50 mg110$1$15
Office visit, established patient, complex (40-54 min)103$135$450
Irrigation of implanted venous access drug delivery device75$18$250
New patient office visit, complex (60-74 min)66$166$495
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less59$45$250
Ct scan of chest with contrast45$84$1,134
CT scan of abdomen and pelvis with contrast43$205$1,800
Nuclear medicine study from skull base to mid-thigh with ct scan28$1,137$7,146
Blood glucose (sugar) measurement using reagent strip27$5$10
Blood glucose (sugar) test performed by hand-held instrument27$3$10
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries23$118$650
New patient office visit (45-59 min)14$130$475
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.8% high complexity
79.3% medium
19.0% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$2,834
Total received (2018-2024)
Avg $472/year across 6 years
Bottom 48% in TX for hematology & oncology
32
Companies
93
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$1,919 (67.7%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$915 (32.3%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$784
2023
$546
2022
$252
2021
$503
2019
$468
2018
$281

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Pharmacyclics LLC, An AbbVie Company
$254
AstraZeneca Pharmaceuticals LP
$241
E.R. Squibb & Sons, L.L.C.
$218
Amgen Inc.
$211
GlaxoSmithKline, LLC.
$210
Seagen Inc.
$200
Novartis Pharmaceuticals Corporation
$197
Intuitive Surgical, Inc.
$140
Astellas Pharma US Inc
$129
PFIZER INC.
$111
Alexion Pharmaceuticals, Inc.
$100
Takeda Pharmaceuticals U.S.A., Inc.
$95
Lilly USA, LLC
$86
Gilead Sciences, Inc.
$81
ABBVIE INC.
$78
Celgene Corporation
$66
JAZZ PHARMACEUTICALS INC.
$61
SOBI, INC
$48
Stemline Therapeutics Inc.
$33
Genentech USA, Inc.
$32
Bayer Healthcare Pharmaceuticals Inc.
$31
Sun Pharmaceutical Industries Inc.
$29
Daiichi Sankyo Inc.
$29
Eisai Inc.
$26
Ipsen Biopharmaceuticals, Inc
$26
Deciphera Pharmaceuticals Inc.
$24
Genmab U.S., Inc.
$21
PUMA BIOTECHNOLOGY, INC.
$16
Boehringer Ingelheim Pharmaceuticals, Inc.
$14
Accord Healthcare, Inc.
$13
Seattle Genetics, Inc.
$12
Janssen Biotech, Inc.
$1
Top 3 companies account for 25.2% of total payments
Associated products mentioned in payments ›
ADCETRIS · BLENREP · CAMCEVI · CYRAMZA · DOPTELET · Da Vinci Surgical System · ELREXFIO · EMPLICITI · EPKINLY · Enhertu · Fabhalta · GILOTRIF · IBRANCE · IMBRUVICA · IMFINZI · IMJUDO · INLYTA · JEMPERLI · KISQALI · Kyprolis · LUTATHERA · Lenvima · Nubeqa · OPDIVO · OPDUALAG · Odomzo · Onivyde · Orserdu · PADCEV · PROMACTA · Phesgo · Pomalyst · QINLOCK · REBLOZYL · SCEMBLIX · SOLIRIS · Stivarga · TAGRISSO · TECENTRIQ · Tivdak · Trodelvy · VELCADE · VONJO · Xtandi · ZEJULA · ZEPZELCA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (68%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $14 per 100 Medicare services performed
Looking for a hematology & oncology in Lufkin?
Compare hematology & oncologys in the Lufkin area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncologys nearby

Geographic Context

Hematology & Oncologys within 10 mi
3
Per 100K population
3.5
County median income
$58,847
Nearest hospital
WOODLAND HEIGHTS MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Pinnamaneni is a mixed practice specialist, with moderate Medicare volume, and low-engagement industry engagement, with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Pinnamaneni experienced with epoetin alfa injection (retacrit) for anemia?
Based on Medicare claims data, Dr. Pinnamaneni performed 5,042 epoetin alfa injection (retacrit) for anemia services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Pinnamaneni receive payments from pharmaceutical companies?
Yes. Dr. Pinnamaneni received a total of $2,834 from 32 companies across 93 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Pinnamaneni's costs compare to other hematology & oncologys in Lufkin?
Dr. Pinnamaneni's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Pinnamaneni) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →